导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.33% | 895/4773 |
| 近一周 | -1.72% | 677/5462 |
| 近一月 | -2.65% | 1358/5421 |
| 近一季 | -4.05% | 1531/5209 |
| 近半年 | -2.95% | 2073/4920 |
| 近一年 | 12.45% | 843/4366 |
| 近两年 | 79.98% | 808/2954 |
| 近三年 | 44.94% | 626/2253 |
| 成立以来 | 100.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.03% 814/4961 |
17.17% 1488/5312 |
- - |
- - |
| 2025 | 29.91% 1362/4813 |
2.16% 1453/3635 |
3.81% 941/4076 |
20.25% 2002/4524 |
1.87% 1178/4813 |
| 2024 | 7.49% 1651/3463 |
-2.79% 1434/2808 |
-5.79% 1797/3014 |
14.88% 1888/3129 |
2.16% 979/3463 |
| 2023 | -4.18% 670/2656 |
8.36% 464/2280 |
-2.98% 727/2385 |
-5.71% 1363/2515 |
-3.34% 662/2655 |
| 2022 | -19.01% 787/2207 |
-13.65% 805/1919 |
3.28% 1180/2016 |
-9.99% 332/2113 |
0.90% 1433/2208 |
| 2021 | 28.67% 80/1822 |
4.64% 141/1255 |
10.78% 436/1330 |
9.14% 144/1466 |
1.70% 832/1822 |
| 2020 | - - |
- - |
- - |
15.20% 230/1164 |
3.17% 940/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信建投中证500增强C VS. 长安沪深300非周期A(740101) |